RICHARD CHIN, M.D.
Osteopathic Medicine at Portal Ave, San Francisco, CA
License number
California A73737
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
58 W Portal Ave #105, San Francisco, CA 94127
Phone
(415) 358-4069
Personal information
See more information about RICHARD CHIN at radaris.comName
Address
Phone
4748 Creekwood Dr, Fremont, CA 94555
5229 Sereno Dr, Temple City, CA 91780
330 Baden Ave APT 102, South San Francisco, CA 94080
325 Wawona St, San Francisco, CA 94127
8109 Hansen Ln, Sebastopol, CA 95472
Organization information
See more information about RICHARD CHIN at bizstanding.comRichard Chin MD
58 W Portal Ave, San Francisco, CA 94127
Industry:
Internist
Phone:
(415) 358-4069 (Phone)
Richard Yoonsik Chin
Professional information
Senior Vice President, Global Sales At Sk Hynix Semiconductor
Position:
Senior Vice President, Global Sales at SK hynix Semiconductor
Location:
San Francisco Bay Area
Industry:
Semiconductors
Work:
SK hynix Semiconductor
since Mar 2012
-
Senior Vice President, Global Sales
SK Telecom Americas
Jan 2008 - Mar 2012
-
President
Motorola
2005 - 2007
-
Corporate Vice President, Global Product Marketing & Business Development
Motorola Mobile Devices
2005 - 2007
-
Corporate Vice President
Education:
The John Marshall Law School
Doctor of Law (JD) University of Chicago
Bachelor of Arts (B.A.), Economics
Doctor of Law (JD) University of Chicago
Bachelor of Arts (B.A.), Economics
Languages:
Korean
Electron Microscopy Labs Manager, Stanford Nanocharacterization Laboratory
Position:
Science & Engineering Associate at Stanford University
Location:
San Francisco Bay Area
Industry:
Nanotechnology
Work:
Stanford University
since Jul 2004
-
Science & Engineering Associate
Education:
Stanford University 1996 - 1998
M.S., Materials Science & Engineering California Institute of Technology 1992 - 1996
B.S., Materials Science
M.S., Materials Science & Engineering California Institute of Technology 1992 - 1996
B.S., Materials Science
Interests:
Professional: TEM (in situ, high resolution, analytical), SEM, FIB, sample preparation, remote microscopy, lab management
Personal: Volleyball, music, reading, cooking, dining, dancing, ...
Senior Vice President, Global Sales At Sk Hynix America
Position:
Senior Vice President, Global Sales at SK hynix America
Location:
San Francisco Bay Area
Industry:
Telecommunications
Work:
SK hynix America
since Mar 2012
-
Senior Vice President, Global Sales
SK Telecom Americas
Jan 2008 - Mar 2012
-
President
Motorola Mobility
Mar 2005 - Aug 2007
-
Corporate Vice President
Education:
University of Chicago 1983 - 1987
Bachelor of Arts (B.A.), Economics The John Marshall Law School
Doctor of Law (JD)
Bachelor of Arts (B.A.), Economics The John Marshall Law School
Doctor of Law (JD)
Languages:
Korean
Member Of Technical Staff At Agilent Technologies
Position:
Member of Technical Staff at Agilent Technologies
Location:
San Francisco Bay Area
Industry:
Semiconductors
Work:
Agilent Technologies
-
Member of Technical Staff
Independent Investment Management Professional
Location:
San Francisco Bay Area
Industry:
Investment Management
Richard Chin, San Francisco CA
Specialties:
Internist
Address:
58 W Portal Ave, San Francisco, CA 94127
Education:
Doctor of Medicine
Reliability For Instant Messaging Based On End Point Acknowledgements
US Patent:
2010007, Mar 18, 2010
Filed:
Sep 15, 2008
Appl. No.:
12/211076
Inventors:
Richard Sinn - Milpitas CA, US
Richard Chin - San Francisco CA, US
Kingston Choy - Fremont CA, US
Richard Chin - San Francisco CA, US
Kingston Choy - Fremont CA, US
Assignee:
Yahoo! Inc. - Sunnyvale CA
International Classification:
G06F 15/16
US Classification:
709206
Abstract:
A reliable IM system is disclosed including an end-to-end mechanism to make sending and receiving IM text messages more reliable. The reliable IM system may include a reliability-enabled client device server device, each including a reliability-enabled messenger component for adding message ID numbers to outgoing IM messages and sending message-specific acknowledgments (ACK) back to a sending client. The reliable IM system may resend a sequenced message N times when the message is identified as missing. The reliability-enabled client and server may be used to communicate with either reliable or non-reliable clients (for example, clients that do not have the reliability-enabled messenger component). An offline storage may be used to accept and store IM messages for offline clients while sending ACKs back for the received messages. Duplicate and lost sequenced messages are handled by deleting duplicate messages and resending lost sequenced messages at the client and/or server to maintain normal IM transactions.
Combination Treatment With T-Pa Variant And Low Molecular Weight Heparin
US Patent:
7084118, Aug 1, 2006
Filed:
Feb 21, 2003
Appl. No.:
10/371778
Inventors:
Paul Armstrong - Edmonton, CA
Hal Barron - San Francisco CA, US
Silvano Berioli - Perugia, IT
Frederique Bigonzi - 1'Hay les Roses, FR
Erich Bluhmki - Schwendi, DE
Richard Chin - San Francisco CA, US
Christopher Granger - Durham NC, US
Frans Van De Werf - Herent, BE
Hal Barron - San Francisco CA, US
Silvano Berioli - Perugia, IT
Frederique Bigonzi - 1'Hay les Roses, FR
Erich Bluhmki - Schwendi, DE
Richard Chin - San Francisco CA, US
Christopher Granger - Durham NC, US
Frans Van De Werf - Herent, BE
Assignee:
Genentech, Inc. - South San Francisco CA
Boehringer Ingelheim Pharmaceuticals, Inc. - Ridgefield CT
Aventis Pharma, S.A. - Antony
Boehringer Ingelheim Pharma KG - Ingelheim/Rhein
Boehringer Ingelheim Pharmaceuticals, Inc. - Ridgefield CT
Aventis Pharma, S.A. - Antony
Boehringer Ingelheim Pharma KG - Ingelheim/Rhein
International Classification:
A61K 38/00, C07K 1/00, C07K 14/00, C07K 17/00
US Classification:
514 12, 530350
Abstract:
The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e. g. AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
Combination Treatment With T-Pa Variant And Low Molecular Weight Heparin
US Patent:
2009000, Jan 1, 2009
Filed:
Aug 4, 2008
Appl. No.:
12/185588
Inventors:
Paul Armstrong - Edmonton, CA
Hal Barron - San Francisco CA, US
Silvano Berioli - Perugia, IT
Frederique Bigonzi - 1'Hay Les Roses, FR
Erich Bluhmki - Schwendi, DE
Richard Chin - San Francisco CA, US
Christopher Granger - Durham NC, US
Frans Van De Werf - Herent, BE
Hal Barron - San Francisco CA, US
Silvano Berioli - Perugia, IT
Frederique Bigonzi - 1'Hay Les Roses, FR
Erich Bluhmki - Schwendi, DE
Richard Chin - San Francisco CA, US
Christopher Granger - Durham NC, US
Frans Van De Werf - Herent, BE
International Classification:
A61K 38/49, A61P 9/10, G06Q 50/00
US Classification:
424 9464, 705500
Abstract:
The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
Richard Chin
Location:
San Francisco Bay Area
Industry:
Semiconductors